Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Temazepam + choline is a combination drug product containing temazepam and choline. Temazepam is a short-acting benzodiazepine that acts as a gamma-aminobutyric acid (GABA) modulator, enhancing the inhibitory effects of GABA in the central nervous system by binding to benzodiazepine receptors on GABA(a) receptors. This increases chloride ion conductance, resulting in hyperpolarization of neuron membranes and reduced neuronal excitation, producing sedative, hypnotic, skeletal muscle relaxant, anticonvulsant, and anxiolytic effects. The combination with choline appears to be formulated as a kit for the management of insomnia, though the specific role of choline in this combination is not fully detailed in the available information. The product is marketed under the brand name Strazepam.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on temazepam + choline.